会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • SENSOR, DELIVERY SYSTEM, AND METHOD OF FIXATION
    • 传感器,传送系统和固定方法
    • WO2007106533A1
    • 2007-09-20
    • PCT/US2007/006441
    • 2007-03-14
    • CardioMEMS, Inc.STERN, DavidWHITE, Jason
    • STERN, DavidWHITE, Jason
    • A61B5/02
    • A61B5/0002A61B5/02007A61B5/021A61B5/02152A61B5/061A61B5/07A61B5/6882
    • An implant assembly for releasing into a vessel at an implant location includes an intracorporeal device and an anchor. The anchor comprises a pair of resiliently deformable loops operatively associated with the intracorporeal device, both of the loops extending toward the same side of a plane defined by the intracorporeal device. The deformable loops have a relaxed state and a deformed state. When the deformable loops are in a relaxed state, the implant assembly has a major dimension in a direction out of the plane that is greater than the diameter of a vessel at the implant location. The loops are deformable to permit insertion of the implant assembly into the vessel. The tendency of the loops to return to their relaxed state exerts a force on a wall of the vessel that imposes the intracorporeal device against an opposite wall of the vessel.
    • 用于在植入位置释放到血管中的植入物组件包括体内装置和锚。 锚固件包括一对与体内装置可操作地相关联的可弹性变形的环,两个环向着由体内装置限定的平面的相同侧延伸。 可变形环具有松弛状态和变形状态。 当可变形环处于松弛状态时,植入物组件在离开平面的方向上具有大于植入位置处的血管直径的主要尺寸。 环可变形以允许将植入物组件插入容器中。 循环回到其松弛状态的趋势在容器的壁上施加力,该力将体内装置施加在容器的相对壁上。
    • 4. 发明申请
    • METHODS FOR REDUCING SEIZURE-INDUCED NEURONAL DAMAGE
    • 减少癫痫诱发神经损伤的方法
    • WO2005042782A1
    • 2005-05-12
    • PCT/US2004/036173
    • 2004-10-28
    • THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKYAN, Shi DuMCKHANN, GuySTERN, David
    • YAN, Shi DuMCKHANN, GuySTERN, David
    • C12Q1/68
    • C07K14/70503A01K67/0275A01K2217/05A01K2227/105A01K2267/03A61K48/00C12N15/8509
    • This invention provides a method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to thereby reduce the extent of neuronal damage in the subject. This invention further provides a method for inhibiting neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure, comprising administering to the subject a prophylactically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to inhibit neuronal damage which would otherwise result from a seizure in the event the subject were to suffer a seizure. This invention further provides related articles of manufacture.
    • 本发明提供了一种在癫痫发作期间或之后治疗受试者的方法,以便减少由于癫痫发作引起的受试者神经元损伤的程度,包括在癫痫发作期间或之后对受试者施用治疗有效的 用于晚期糖基化终产物(RAGE)的受体抑制剂的量,从而减少受试者的神经元损伤的程度。 本发明进一步提供了一种抑制神经元损伤的方法,否则这些损伤将由预先发生癫痫发作的受试者的癫痫发作引起,其包括向受试者施用预防有效量的晚期糖基化终末产物受体抑制剂(RAGE),以便 以抑制在受试者遭受癫痫发作的情况下由于癫痫发作而导致的神经元损伤。 本发明还提供了相关的制造品。
    • 7. 发明申请
    • METHODS FOR TREATING MULTIPLE SCLEROSIS
    • 治疗多发性硬化症的方法
    • WO2005042032A1
    • 2005-05-12
    • PCT/US2004/036170
    • 2004-10-28
    • THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKYAN, Shi, DuSTERN, David
    • YAN, Shi, DuSTERN, David
    • A61K48/00
    • A61K31/00A61K38/1774
    • This invention provides a method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of soluble receptor for advanced glycation endproducts (sRAGE). This invention further provides a method for inhibiting CD4 + T-cell migration comprising contacting the CD4 + T-cell with soluble receptor for advanced glycation endproducts (sRAGE). This invention further provides a method for inhibiting chemokine receptor activation in a subject comprising administering to the subject a therapeutically effective amount of soluble receptor for advanced glycation endproducts (sRAGE). Finally, this invention provides related articles of manufacture.
    • 本发明提供了治疗患有多发性硬化症的受试者的方法,其包括向受试者施用治疗有效量的晚期糖基化终产物(sRAGE)的可溶性受体。 本发明进一步提供了一种抑制CD4 + T细胞迁移的方法,包括使CD4 + T细胞与晚期糖基化终产物(sRAGE)的可溶性受体接触。 本发明进一步提供了一种用于抑制受试者中趋化因子受体活化的方法,其包括向受试者施用治疗有效量的晚期糖基化终产物(sRAGE)的可溶性受体。 最后,本发明提供了相关的制造品。